Patrick M. Caldwell
Keine laufenden Positionen mehr
Karriereverlauf von Patrick M. Caldwell
Ehemalige bekannte Positionen von Patrick M. Caldwell
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BIOSPECIFICS TECHNOLOGIES CORP. | Comptroller/Controller/Auditor | 01.04.2019 | 02.12.2020 |
| Finanzdirektor/CFO | 01.04.2019 | 06.01.2020 | |
| Corporate Officer/Principal | - | 01.04.2019 | |
| Meta Software, Inc. | Comptroller/Controller/Auditor | - | 05.07.2019 |
Protein Design Labs, Inc.
 Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Comptroller/Controller/Auditor | - | - |
| Finanzdirektor/CFO | - | - |
Ausbildung von Patrick M. Caldwell
| San Jose State University | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Comptroller/Controller/Auditor | 3 |
| Director of Finance/CFO | 2 |
| Corporate Officer/Principal | 1 |
Sektoral
| Health Technology | 3 |
| Finance | 2 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Protein Design Labs, Inc.
Protein Design Labs, Inc. Pharmaceuticals: MajorHealth Technology Protein Design Labs, Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a company of development of humanized antibodies, It has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products. | Health Technology |
BioSpecifics Technologies Corp.
 BioSpecifics Technologies Corp. Pharmaceuticals: MajorHealth Technology BioSpecifics Technologies Corp. engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. It sells its products under the brand XIAFLEX. The company was founded in 1990 and is headquartered in Lynbrook, NY. | Health Technology |
| Meta Software, Inc. | Finance |
- Börse
- Insiders
- Patrick M. Caldwell
- Erfahrung